The Founders ReportIntelligence for founders who build
Home/Founder Profiles/Founder Profile
Founder Profile

How Nara Patel Rebuilt Vantage Health's GTM From Outbound to Product-Led After $2M ARR

The 14-month transition that cost 30% of the sales team, doubled trial-to-paid conversion, and changed the unit economics of the entire business.

How Nara Patel Rebuilt Vantage Health's GTM From Outbound to Product-Led After $2M ARR
T
Featured Founder

The Founders Report

Editorial Desk

TFRProfile

In March 2025, Nara Patel was running a company that looked healthy on the surface. Vantage Health, her compliance automation platform for mid-market healthcare organizations, had crossed $2M in ARR with a 14-person team. The outbound engine was generating pipeline. Deals were closing. But the numbers underneath were deteriorating in ways that would not show up in a board deck for another two quarters.

The signal that started the transition

Patel noticed that customers acquired through inbound trial requests retained at 94% after twelve months. Customers acquired through outbound SDR outreach retained at 71%. The outbound customers also required 3x more onboarding support and generated 40% more support tickets in their first 90 days. The outbound motion was producing revenue. It was also producing the customers most likely to leave.

"We were spending $38,000 in fully-loaded cost to acquire customers who would churn in 14 months," Patel said. "The math only worked if we never looked past the first renewal."

The decisions that defined the transition

Patel restructured the GTM in three phases over 14 months. First, she froze outbound hiring and redirected that budget into product-led onboarding: a self-serve trial, in-product activation sequences, and usage-based triggers for sales engagement. Second, she reduced the SDR team from six to two, keeping only the reps who could operate as product consultants rather than cold callers. Third, she rebuilt the sales comp model around expansion revenue rather than new logo acquisition.

The transition cost her three senior salespeople who left voluntarily, a board member who questioned the timing publicly, and a quarter where net new ARR dropped 45%. "Q3 2025 was the worst quarter of my career," Patel said. "We had dismantled the old engine and the new one was not producing yet."

The outcome at eighteen months

By Q1 2026, Vantage Health had crossed $4.1M ARR. Trial-to-paid conversion was running at 18%, up from 6% before the product-led investment. Net revenue retention hit 127%. The sales team was smaller but closing larger contracts, because the product-led motion pre-qualified buyers before a human ever entered the conversation. CAC payback dropped from 19 months to 8.

The lesson Patel draws is structural, not tactical: "The GTM motion is not a layer on top of the product. It is an expression of who your best customer is. If your best customers find you through the product, your GTM should start there. Everything else is expensive misdirection."